Screener
Madrigal Pharmaceuticals, Inc. MDGL Accounts Receivable
Accounts Receivable at other companies
Other financials
Where this comes from
Reported directly by Madrigal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccountsReceivableNetCurrent.
The source filing: Madrigal Pharmaceuticals, Inc.’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 9:06 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-050845
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Cash and cash equivalents | $292,726 | $198,693 |
| Restricted cash | 155 | 5,090 |
| Marketable securities | 546,027 | 784,866 |
| Trade receivables, net | 192,311 | 134,476 |
| Inventory | 99,391 | 74,841 |
| Prepaid expenses and other current assets | 68,570 | 47,804 |
| Total current assets | 1,199,180 | 1,245,770 |
| Property and equipment, net | 11,592 | 1,499 |
Item 1. Financial Statements (Unaudited):
FAQ
- What is Madrigal Pharmaceuticals, Inc.'s accounts receivable?
- Madrigal Pharmaceuticals, Inc. (MDGL) reported accounts receivable of $192.31M in Q2 2026.
- How has Madrigal Pharmaceuticals, Inc.'s accounts receivable changed year-over-year?
- Madrigal Pharmaceuticals, Inc.'s accounts receivable increased by 142.7% year-over-year, from $79.23M to $192.31M.
- What does accounts receivable mean?
- Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.
Ask your AI about Madrigal Pharmaceuticals, Inc.'s accounts receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude